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Background: 15% of atopic dermatitis liability-scale heritability could be attributed to 31 
susceptibility loci identified by genome-wide association studies, with only three of them 
(IL13, IL6R, and FLG) resolved to protein-coding variants. 
Objective: We examined whether a significant portion of unexplained atopic dermatitis 
heritability is further explained by low-frequency and rare variants in gene coding 
sequence. 
Methods: We evaluated common, low-frequency and rare protein-coding variants using 
exome chip and replication genotype data of 15,574 patients and 377,839 controls, 
combined with whole transcriptome data on lesional, non-lesional and healthy skin 
samples of 27 patients and 38 controls. 
Results: Additional 12.56% (s.e. 0.74%) of atopic dermatitis heritability is explained by 
rare protein-coding variation. We identified Docking protein 2 (DOK2) and CD200 
Receptor 1 (CD200R1) as novel genome-wide significant susceptibility genes. Rare coding 
variants associated with atopic dermatitis are further enriched in five genes (IL4R, IL13, 
JAK1, JAK2, TYK2) of the IL13 pathway, all of which are targets for novel systemic atopic 
dermatitis therapeutics. Multiomics-based network and RNA-Sequencing analysis 
revealed DOK2 as a central hub interacting, among others, with CD200R1, IL6R and 
STAT3. Multi-tissue gene expression profile analysis for 53 tissue types from GTEx 
showed that disease-associated protein-coding variants exert their greatest effect in skin 
tissues.  
Conclusion: Our discoveries highlight a major role of rare coding variants in atopic 
dermatitis acting independently of common variants. Further extensive functional studies 
are required to detect all potential causal variants and to specify the contribution of novel 







• This exome chip analysis for atopic dermatitis identified two novel susceptibility 
genes (DOK2, CD200R1), and signalling through CD200/CD200R1/DOK2 could be an 
important new regulatory signalling pathway in AD. 
     • Disease-associated rare coding variants are enriched in five genes of the IL13 
pathway, which are targets for novel systemic atopic dermatitis therapeutics in advanced 
stages of clinical investigations. 
     • In total 12% of atopic dermatitis heritability is further explained by rare genetic 
variation thus highlighting the importance to study the impact of rare protein-coding 





Protein coding variants in DOK2, CD200R1 and genes of the IL13 pathway contribute to 






Atopic dermatitis; exome chip association analysis; network analysis; protein sequence and structural 





A1 : Minor allele 
A2 : Major allele 
AA : Amino acid 
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 Atopic dermatitis (AD; MIM: 603165) is the most common chronic inflammatory skin 
disorder affecting 15–20 % of children and 5–10 % of adults (~280 million people worldwide), 
and the leading cause of the non-fatal disease burden conferred by skin conditions(1). Given its 
high genetic heritability (71-84 % in Europeans)(2), finding causal genes is a crucial step for 
developing effective preventive and therapeutic approaches for AD. GWAS so far have 
identified 31 specific genomic regions associated with AD susceptibility(3-9). The reported 
susceptibility variants are common (n = 31 with MAF ≥ 5 %) and mostly located in non-coding 
DNA regions of the genome, have rather small effect sizes (odds ratio (OR) < 1.15) and a 
largely unclear functional significance(9). Notable exceptions are low-frequency null mutations 
in the gene encoding the epidermal structural protein filaggrin (FLG), which lead to a reduction 
in biologically active filaggrin peptides, and a complex perturbation of skin barrier 
function(10), as well as common missense variants in the genes encoding the T helper 2 (Th2) 
signature cytokine IL13 (IL13; rs20541)(11) as well as the IL6 receptor (IL6R; rs2228145)(12). 
Recently, an exome chip based association study of low-frequency variation across all 
autosomal exons in multiple sclerosis (MS) cohorts of European ancestry led to the detection 
of low-frequency MS-associated coding variants for four genes that were missed by previous 
large-scale MS consortium GWAS(13) and that explain another 5% of MS heritability, thus 
reopening the debate on the contribution of low-frequency and rare variants to disease risk in 
complex diseases.  
 To systematically evaluate the contribution of genetic variation to the genetic 
architecture of AD on the exome-wide scale, particularly protein-altering variants of low or 
rare-frequency, we profiled 1,913 AD patients and 14,295 controls in two German cohorts using 
the Illumina HumanExomeBeadchip (exome chip) (see Supplementary Table E1 in Online 
Repository). The exome chip captures approximately 88 % of low-frequency and rare-coding 
variants (non-synonymous, splice-site and stop altering, MAFs between 0.01 % and 5 %) 
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present in Europeans(14). Suggestive significant novel associations (pexomechip < 1×10
-5) were 
taken forward to replication genotyping in a third German cohort of 1,789 AD cases and 3,272 
controls, a Danish exome chip case-control study of 292 severe AD cases and 650 controls, 
GWAS association statistics of the EAGLE eczema consortium of 2,298 independent AD cases 
and 7,802 controls (see Supplementary Table E1 in Online Repository) as well as association 
summary statistics of 361,132 individuals from UK Biobank with self-reported information 
(see Supplementary Table E1 in Online Repository). Gene-based tests and Bayesian fine-
mapping analysis as well as whole transcriptome RNA-seq, immunohistochemistry and variant 
protein analyses were conducted to elucidate potential functional consequences of coding 
variation associated with AD. Finally, we performed multiomics-based network, pathway gene 
set and gene expression tissue profile analyses, and we quantified the overall contribution of 





The Methods section in this article’s Online Repository provides details on the methods used 
in this study. 
 
Study samples and genotyping 
All cases had been diagnosed with AD by a dermatologist except for UK Biobank cases. 
All participants provided written informed consent and the study was approved by the ethics 
boards of the participating institutions, in agreement with the Declaration of Helsinki principles. 
 German discovery cohort 1. German AD patients (n = 1,056) were recruited at the 
Department of Dermatology at Christian-Albrechts-University Kiel, Department of 
Dermatology and Allergy at the Technical University of Munich, and the Department of 
Dermatology and Allergy at the University of Bonn. Data from healthy control individuals 
(n = 7,026) were obtained from the PopGen biobank(15), the KORA S4 survey (an independent 
population-based sample from the general population living in the region of Augsburg, southern 
Germany)(16) and the Heinz-Nixdorf Recall (HNR) cohort(17), Bonn. AD cases as well as 
controls were genotyped using Illumina HumanExome-12 v1.0 BeadChips (see Supplementary 
Table E1 in Online Repository). 
 German discovery cohort 2. German AD patients (n = 1,051) were recruited from 
dermatology clinics in Kiel or Hannover (the University of Kiel and Medizinische Hochschule 
of Hannover). The AD cases were genotyped using Illumina HumanCoreExome-24 v1.0 A or 
HumanCoreExome-24 v1.1 A BeadChips. Data from healthy control individuals (n = 8,135) 
were obtained from the SHIP and SHIP-TREND cohorts (from the Study of Health in 
Pomerania, a prospective longitudinal population-based cohort study in West Pomerania)(18). 
All German controls were genotyped using Illumina HumanExome-12 v1.0 BeadChips (see 
Supplementary Table E1 in Online Repository). 
 
13 
 German replication cohort. German AD patients (n = 1,789) were recruited from 
dermatology clinics in Kiel or Berlin (University Children’s Hospital, Charité 
Universitätsmedizin Berlin, as part of the Genetic Studies in Nuclear Families with AD 
(GENUFAD) study). Data from healthy control individuals (n = 3,272) were obtained from 
University Hospital in Kiel and Lübeck at the Institute of Transfusional Medicine (see 
Supplementary Table E1 in Online Repository). 
 Danish replication cohort. All Danish AD cases (n = 292) are hospitalized severe cases 
from the COPSAC eczema REGISTRY. Healthy control individuals (n = 650) were obtained 
from the COPSAC2000 and COPSAC2010 birth cohorts(19) in Copenhagen, Denmark. Both, 
cases and controls were genotyped on the Illumina Infinium OmniExpressExome-8 v1.4 
BeadChip (see Supplementary Table E1 in Online Repository). 
 EAGLE GWAS replication cohorts. We used imputed summary statistics of the EAGLE 
Eczema Consortium for the discovery cohorts (excluding 23andMe). 
(https://data.bris.ac.uk/data/dataset/28uchsdpmub118uex26ylacqm) comprising 11,294,660 
SNP markers with MAF ≥ 1 % and 10,788 AD cases and 30,047 controls (see Supplementary 
Table E1 in Online Repository).(9) For replication analysis, we used only European studies 
independent from our German discovery cohorts and where AD diagnosis was ascertained by 
a dermatologist.  
 UK Biobank. Since only 33 (primary diagnosis; field 41203) and 50 patients (secondary 
diagnosis; field 41204) have been diagnosed with “atopic dermatitis” (ICD10 code L30) in UK 
Biobank, we used questionnaire information from UK Biobank (release of March 2018). Key 
words “atopic dermatitis” and/or “eczema” are contained in self-reported data-fields“ Non-
cancer illness code; self-reported: eczema/dermatitis” (data-field 20002) and “Age hay fever, 
rhinitis or eczema diagnosed” (data-field 3761) and three others (data-fields 6152, 41202, 
41203). For the three lead variants (DOK2: rs34215892; rs56094005; CD200R1: rs9865242), 
we downloaded imputed summary association statistics (http://www.nealelab.is/uk-biobank/; 
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http://www.nealelab.is/uk-biobank/faq; release March 2018; see Supplementary Table E1 in 
Online Repository) for (a) 83,407 cases with eczema, allergic rhinitis or/and hayfever (data-
field 20002) versus 277,120 controls and (b) 9,312 cases with eczema or dermatitis (data-field 
3761) versus 351,820 controls. 
 An overview of the study design is shown in Supplementary Figure E1 in Online 
Repository, and detailed characteristics of the discovery and replication case-control cohorts 





[Exome chip single-variant association analysis] 
 In our exome chip discovery search for common, low-frequency and rare variant 
associations, two German AD discovery cohorts were combined via a meta-analysis resulting 
in single variant association analysis score statistics of 143,884 genotyped and 1,357,289 single 
nucleotide variants after imputation with info score ≥ 0.5 (see Supplementary Figure E1-2, 
Supplementary Table E2 in Online Repository, see Methods in Online Repository). 438 and 
1,331 SNPs within 7 and 25 loci were identified with genome-wide significance 
(pexomechip < 5×10
-8) and suggestive association (pexomechip < 1×10
-5), respectively (see also 
Supplementary Figure E3, Supplementary Table E3 in Online Repository). To identify novel 
susceptibility variants outside of established AD GWAS loci (see Supplementary Table E4 in 
Online Repository) eleven suggestively associated SNPs (pexomechip < 10
-5 with MAF ≥ 1 %) 
were selected based on LD clumping method (see Methods in Online Repository) and carried 
forward for replication (Supplementary Table E5 in Online Repository). Using the genome-
wide threshold of 5×10-8 for the combined analysis of discovery and replication (see Methods 
in Online Repository), we identified a novel low frequency missense variant in exon 3 of the 
gene Docking protein 2 (DOK2 at 8p21.3; rs34215892 (p.P274L); pexomechip = 9.83×10
-7; 
genotyped variant) which consistently and robustly replicated in three independent cohorts 
(pGerman = 3.75×10
-4; pDenmark = 7.60×10
-3; pEAGLE = 4.35×10
-2; pcombined = 2.15×10
-10; 
ORcombined = 0.64; Table 1; see Supplementary Table E5 in Online Repository). Further, we 
detected a novel association between AD and a common missense variant at 3q13.2 (rs9865242; 
p.E312Q; pcombined = 1.17×10
-7; ORcombined = 1.16; genotyped variant; see Supplementary Table 
E5 in Online Repository) located in exon 7 of CD200 Receptor 1 (CD200R1) and 266.51 kb 
upstream of the previously reported intergenic locus 3q13.2 (CCDC80, rs12634229) described 
only in a Japanese AD cohort(6) so far (r²rs9865242-rs12634229 = 0.005). A look-up of association 
results from UK Biobank for the self-reported broad allergic disease phenotype “AD (eczema), 
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allergic rhinitis and/or hayfever”(20) (see Methods in Online Repository) further confirmed 
association signals for DOK2 (rs34215892; pUK-Biobank = 3.35×10
-6) and CD200R1 (rs9865242; 
pUK-Biobank = 1.35×10
-8) (Table 1). 
 
[Exome chip gene-based association analysis] 
Due to insufficient statistical power to perform single marker tests for rare variants, we 
performed gene-based association analysis, in which we evaluated the cumulative effects of 
low-frequency and rare variants (non-synonymous, stop-gain and essential splice site; 
n = 118,816 exome chip variants excluding imputed variants) for each gene from autosomes 
(see Methods in Online Repository). Only DOK2 met the exome-wide significance threshold 
(see Methods in Online Repository) and exhibited a stronger association signal than compared 
to single variant analysis (pcombined-DOK2 = 4.23×10
-13; Table 2; see Supplementary Table E6 in 
Online Repository) comprising twelve protein-altering variants of which two were of low-
frequency and LD-independent (rs34215892 and rs56094005; 1 % ≤ MAF < 5 %) and ten were 
rare (MAF < 1 %) (Figure 1). We genotyped the second low-frequency variant rs56094005 
(p.L138S; prs56094005-exomechip = 4.31×10
-3; genotyped variant) in our replication set, in addition 
to rs34215892, and successfully confirmed the single SNP (prs56094005-replication = 5.96×10
-3; see 
Supplementary Table E5 in Online Repository) and the aggregated DOK2 association signal 
(pDOK2-replication = 1.54×10
-6; see Supplementary Table E6 in Online Repository). 
 
[Bayesian fine-mapping and functional annotation] 
 As a next step towards understanding the functional causality of the identified AD-
associated variants, we carried out Bayesian fine-mapping and functional annotation analysis 
for loci CD200R1 and DOK2 using imputed exome chip data of our discovery cohorts (see 
Methods in Online Repository). Fine-mapping strengthened our hypothesis that lead variants 
rs9865242 (CD200R1) and rs34215892 (DOK2) as being most likely causal (in the context of 
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fine-mapping), with posterior probabilities of 97.2 % and 44.3 %, respectively (see 
Supplementary Figure E4 in Online Repository). rs34215892 overlaps enhancer histone 
marks and DNase peaks in 15 and 12 different tissues respectively, in each case including the 
skin, and is predicted to affect protein binding and regulatory motifs (see Supplementary Table 
E7 in Online Repository). The second DOK2 lead variant rs56094005 (Figure 1) overlaps 
promoter histone marks and DNase peaks in ten tissues, in each case including T and B cells, 
and is in perfect LD (r² = 1) with an intronic variant rs118162691 (prs118162691-
exomechip = 4.17×10
-3; MAF = 3.9 %) which overlaps enhancer histone marks in nine different 
tissues including the skin (see Supplementary Table E7 in Online Repository). The CD200R1 
missense variant rs9865242 has been suggested as a cis-eQTL for GTPBP8 in whole blood(21). 
Ten variants in perfect LD with rs9865242, further overlapping enhancer histone marks in 
blood predicted to alter regulatory motifs, are located in a conserved region or are found as 
eQTLs for CD200R1(22) (see Supplementary Table E7 in Online Repository).  
 
[Immunohistochemistry and whole transcriptome mRNA-seq data analysis] 
 Immunohistochemistry was used to determine the location of DOK2 in skin tissue (see 
Methods in Online Repository). It showed strong epidermal staining with clear differences 
among AD lesional, AD non-lesional and healthy skin (see Supplementary Figure E5 in 
Online Repository). DOK2 is predominantly expressed in lymphocytes and the increased 
abundance of DOK2 in lesional AD skin correlates with the degree of lymphocyte infiltration 
(see Supplementary Figure E5 in Online Repository). Moreover, we observed a significantly 
increased DOK2 and CD200R1 mRNA expression in whole transcriptome mRNA-seq data (see 
Methods in Online Repository) on lesional as compared to non-lesional skin samples of 27 AD 
patients (pDOK2 = 4.2×10
-5, pCD200R1 = 2.2×10
-5) and as compared to skin from 38 healthy 
individuals (pDOK2 = 8.8×10
-11, pCD200R1 = 2.2×10
-7), as well as in AD non-lesional skin 
compared to healthy skin (pDOK2 = 4.5×10
-3, pCD200R1 = 2.0×10
-2) (see Supplementary Figure 
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E6a-b in Online Repository). We also observed a trend of increased expression of DOK1, 
whose protein is a heterodimeric partner for DOK2, in lesional skin compared to non-lesional 
(pDOK1 = 1.1×10
-1) or healthy skin (pDOK1 = 3.1×10
-4), as well as non-lesional skin compared to 
healthy skin (pDOK1 = 4.0×10
-3) (see Supplementary Figure E6c-d in Online Repository). 
 
[In silico variant protein analysis] 
 To construct a first hypothetical model of whether CD200R1 and DOK2 missense lead 
variants are likely to interfere with functionally active domains on the protein level, we 
performed extensive literature search and further conducted protein domain analyses of DOK2 
and the CD200/CD200R1 receptor complex (see Methods in Online Repository) (Figure 2). 
Members of the DOK adapter protein family act as regulators of cell stimulatory signals by 
serving as substrates for diverse receptor and cytoplasmic kinases, and the highly similar and 
interacting members DOK1 and DOK2 are involved in the down-regulation of immune receptor 
signalling in CD4+ T cells as well as myeloid cells such as macrophages and neutrophils(23). 
It is assumed that the inhibitory role of DOK2 is accomplished by recruiting and activating 
RasGAP to inhibit Ras and thus to suppress pro-inflammatory ERK, JNK and MAPK pathways 
for the DOK2 response to CD200R1 in human myeloid cells(24). Activated RasGAP inhibits 
mitogen-activated kinase (MAPK) signalling and subsequently reduces production of pro-
inflammatory cytokines such as TNFα, INFγ, IL1, IL17, IL6, IL8(25, 26). By means of our 
protein sequence and structure analyses we observed that variant rs56094005 (p.L138S) locates 
within a linker sequence between the PH and the PTB domain adjacent the Y139 
phosphorylation-dependent DOK1 interaction site and may interfere with heterodimerization 
of DOK1 and DOK2 required for full phosphorylation of the two proteins and signalling(27). 
Variant rs34215892 (p.P274L), located in the invariant RasGAP-SH2 binding consensus motif 
YxxPxD(27), is likely affecting local protein structure conformation due to the unique structural 
rigidity of the proline side chain and therefore predicted to interfere with RasGAP signalling. 
 
19 
Assuming an important stabilizing structural role of the proline within the binding motif, the 
variant p.P274L is likely to disturb the RasGAP activation by DOK2. The amino acid 
substitution of E to Q of variant rs9865242 (p.E312Q) causes a loss of negative charge in 
proximity of the NPLY motif and protein interaction site and may therefore modify protein-
protein contacts and signalling(28).  
 
[AD core network construction and differential gene expression analysis of core genes] 
 In order to assess possible interactions of genes CD200R1 and DOK2 with candidate 
genes from AD GWAS loci(3-9), we generated an AD core interaction network using network 
prioritization algorithms which make use of protein-protein, protein-gene, co-expression, and 
shared protein domains data from public repositories (see Supplementary Figure E7; 
Supplementary Table E8 in Online Repository; see Methods in Online Repository). We 
identified DOK2 as a central hub node interacting with CD200R1 and functionally established 
AD susceptibility genes STAT3(9), MICB(29), CLEC16A(8) and IL6R(12) (Figure 3a). We 
used our aforementioned whole transcriptome mRNA-seq data (see Methods in Online 
Repository) to assess whether expression levels from genes of our AD core network are 
differentially expressed in lesional, non-lesional and healthy skin from AD patients and healthy 
individuals. 22 out of the 30 AD core genes (Figure 3a) are significantly up or downregulated 
(see Supplementary Table E9; Supplementary Figure E8 in Online Repository), with 17 out 
of 22 directly interacting with DOK2 (Figure 3b), thus indicating the biological importance of 
DOK2 in AD pathogenesis. 
 
[Pathway and gene expression tissue specificity analysis for exome chip variants] 
 To reveal potential differences in terms of biological pathways and involved tissues for 
exome chip variant (exome chip) and common variants investigated in AD GWAS meta-
analysis studies (GWAS) from the EAGLE consortium, we performed gene-set pathway 
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enrichment analysis for curated gene sets and gene ontology (GO) terms as well as tissue-
specific gene expression profile analysis(30) for 53 tissue types and 11,688 samples from GTEx 
release 7 (see Methods in Online Repository). The pathway enrichment analysis identified one 
significant gene set including five genes (PBonferroni < 0.05; IL4R, IL13, JAK1, JAK2, TYK2) of 
the IL13 pathway for the exome chip in comparison to eight blood-cell related gene sets 
(including regulation of immunoglobulin production, B cell activation and B cell mediated 
immunity) for the EAGLE GWAS data. Recently, AD was characterized as an IL13-dominant 
disease based on high-depth RNA-seq transcriptome data of 147 samples from cohorts of AD 
patients, psoriasis patients, and healthy controls, with IL13 being the most distinctive marker 
for AD(31). We hypothesize that low-frequency and rare coding variants in genes of the IL13 
pathway are further likely to be associated with AD. In the tissue specificity analysis, we tested 
for relationships between tissue-specific gene expression profiles and variant association 
statistics from exome chip and GWAS, respectively. For the exome-chip data, we observed a 
Bonferroni-corrected significant association (P < 9.43×10-4) with two skin tissue types (sun 
exposed and non-sun exposed skin; Figure 4a). In comparison the EAGLE GWAS data 
revealed a significant association with tissues whole blood and spleen (Figure 4b). Thus, exome 
chips variants cumulatively may have a stronger effect on skin tissue gene expression than 
common variants interrogated in AD consortium GWAS analyses. 
 
[Estimation of liability-heritability from exome chip variants] 
 To quantify the overall contribution of exome chip variation to AD risk, i.e. estimating 
the exome-wide contribution of (mainly rare) protein-coding variants to the liability-scale 
heritability for AD, we used a restricted maximum-likelihood approach to model heritability 
attributable to genotypic variation across genotyped-only exome chip variants (see Methods in 
Online Repository). We found that common variants from exome chip (LD pruned, 
MAF ≥ 5 %; see Methods in Online Repository) explain 1.04 % of heritability on the observed 
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scale (corresponding to 2.93 % on the liability scale assuming a prevalence of 0.14). By 
lowering the MAF threshold to 1%, exome chip heritability increased to 1.27 % (3.60 %). 
Dividing variants into low-frequency (1 % ≤ MAF < 5 %) and rare (MAF < 1 %), 
heritability was found to be 0.37 % for low-frequency variants (0.94 %) and 4.47 % for rare 
variants (12.56 %). Furthermore, we estimated the heritability explained by the newly identified 
lead variants of DOK2 (rs3215892, rs56094005) and CD200R1 (rs9865242). Variants 
rs3215892, rs56094005 and rs9865242 explain approximately 0.015 % (0.041 %), 0.004 % 





In conclusion, we analysed the association of AD with common, low-frequency and rare 
protein-coding variants and implicate two novel genes (DOK2 and CD200R1) contributing to 
AD risk. So far, 14.91 % (6.95 % excluding FLG mutations) of AD liability-scale heritability 
could be attributed to common lead variants of 31 GWAS loci, estimated from a set of 5,775 
clinically diagnosed AD patients and assuming a population prevalence of 0.15(3-9). Recently, 
Ferreira et al.(20) further reported a genome-wide liability-scale heritability estimate of 9.04 % 
from 1.2 million HapMap SNPs (assuming a population prevalence of 0.14) and on the basis of 
self-reported information from questionnaires. Our newly identified variants (rs3215892, 
rs56094005, rs9865242) explain another 0.088 % of the variance in liability. Interestingly, 
approximately 12.56 % (s.e. 0.74 %) of liability-scale heritability is estimated to be explained 
by rare protein-coding variants (MAF < 1 %), thus highlighting the importance to study rare 
coding variation in AD. Since these heritability estimates originate from predominantly 
European study populations, performing GWAS and exome chip studies in more diverse 
populations is crucial to optimize heritability estimation for AD in the future. Our results 
encourage future studies along the same path and highlight the importance to study the impact 
of protein-coding variants for phenotypically well-defined clinically diagnosed cohorts.  
Pathway enrichment analysis of exome chip data revealed that association signals of 
low-frequency and rare coding variants are enriched in five genes of the IL13 pathway, all of 
which are targets for novel systemic AD therapeutics in advanced stages of clinical 
investigations(32), supporting the pivotal role of type 2 inflammation in AD pathogenesis(1). 
Gene expression tissue profile analysis showed that exome chip variants associated with AD 
cumulatively have a stronger effect on skin tissue gene expression than common GWAS 
variants associated with AD, as identified in combination with whole transcriptome RNA-
sequencing data on lesional, non-lesional and healthy skin tissue as well as tissue samples from 
GTEx. In accordance with results from the exome chip study for multiple sclerosis(13), we 
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observed that the minor allele of low-frequency lead missense variants in DOK2 is mostly 
protective (in context of the odds ratio; Table 2). 
The newly discovered genes DOK2 and CD200R1 have clear immunological functions, 
confirming that AD pathogenesis is primarily driven by immune dysregulation. Structural 
protein domain analysis, topological network and differential gene expression analyses suggest 
that missense variants in DOK2 (rs34215892; rs56094005) in combination with the missense 
AD risk variant in CD200R1 (rs9865242) together may affect tyrosine phosphorylation sites in 
DOK2 and CD200R1 (Figure 2). DOK2 belongs to the DOK gene family encoding for seven 
different DOK proteins (DOK1–7) being involved in signal transduction(27, 33-35). DOK1–2 
are adaptor proteins and mainly expressed in hematopoietic/immune cells(36) and have been 
implicated to negatively regulate proliferation and constitutive expression of DOK2(37). 
Further studies showed that both DOK1–2 are essential negative regulators of ERK signalling 
downstream of Toll-like receptor 4(38). Mice lacking DOK1–3 showed significant defects in 
immune cell development and in immune responses(39). Furthermore, DOK1–2 play a role in 
the maturation of NK cells(40), which have been shown to be reduced in AD. In line with these 
observations, we observed a significantly increased DOK2 and CD200R1 mRNA expression in 
lesional as compared to non-lesional skin samples of AD patients, and as compared to skin from 
healthy individuals. Our AD core network (Figure 3) further showed that DOK2 acts as a 
central hub gene interacting with CD200R1 as well as several candidate AD GWAS 
susceptibility genes on the cellular level. Our AD core network revealed 21 genes that are 
directly functionally related to DOK2 of which 16 are significantly upregulated (including 
DOK1) and one (RASGAP) is significantly downregulated in lesional skin samples of AD 
patients. Taking into account the reported inflammatory role of both DOK2 and CD200R1, we 
conclude that signalling through CD200/CD200R1/DOK2 could be an important new 
regulatory signalling pathway in AD. Extensive functional studies are required to detect all 
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potential causal variants and thus to specify the contribution of the DOK2 and CD200R1 to 
overall disease susceptibility. 
 
Author contributions 
 A.F., S.W. and D.E conceived and designed the study. A.F. and D.E. supervised the 
study. W.L., M.M-N., M.M.N., P.H., A.A., G.H., C.O.M., M.S., K.B., T.S.A., H.Bi., D.S., S.G., 
A.P., C.G., M.Wa., H.S., T.W., E.R., K.S., T.W., R.F-H., N.N., M.Ho., P.R., S.S., Y.-A. L., 
and S.W. contributed to sample collection and phenotyping. S.M., D.E., E.R. and E.E. executed 
sample handling, genotyping and/or quality control. U.W. performed evaluation of 
immunohistochemistry. G.M. performed in silico variant protein analysis. S.M. and H.B. 
performed statistical and bioinformatics analysis for the discovery and the combined meta 
analyses, while T.S.A. performed statistical analysis for the Danish replication cohort and S.G., 
I.M. performed statistical analysis for UK Biobank. H.E., F.D., M.Hü., J.C.K., L.W. and D.E. 
helped with bioinformatic analyses. S.B., M.W., O.W., S.M. and D.E. performed network 
analysis. S.M., H.B., G.M., E.E., E.S.J., N.D., L.P., S.W., A.F. and D.E. participated in 
interpretation of results. S.M., H.B. and D.E. wrote the manuscript. All authors critically 






1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-22. 
2. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century 
perspective. Immunol Rev. 2011;242(1):10-30. 
3. Schaarschmidt H, Ellinghaus D, Rodriguez E, Kretschmer A, Baurecht H, Lipinski S, 
et al. A genome-wide association study reveals 2 new susceptibility loci for atopic dermatitis. 
J Allergy Clin Immunol. 2015;136(3):802-6. 
4. Esparza-Gordillo J, Weidinger S, Folster-Holst R, Bauerfeind A, Ruschendorf F, 
Patone G, et al. A common variant on chromosome 11q13 is associated with atopic 
dermatitis. Nat Genet. 2009;41(5):596-601. 
5. Sun LD, Xiao FL, Li Y, Zhou WM, Tang HY, Tang XF, et al. Genome-wide 
association study identifies two new susceptibility loci for atopic dermatitis in the Chinese 
Han population. Nat Genet. 2011;43(7):690-4. 
6. Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Sakashita M, et al. Genome-
wide association study identifies eight new susceptibility loci for atopic dermatitis in the 
Japanese population. Nat Genet. 2012;44(11):1222-6. 
7. Paternoster L, Standl M, Chen CM, Ramasamy A, Bonnelykke K, Duijts L, et al. 
Meta-analysis of genome-wide association studies identifies three new risk loci for atopic 
dermatitis. Nat Genet. 2011;44(2):187-92. 
8. Ellinghaus D, Baurecht H, Esparza-Gordillo J, Rodriguez E, Matanovic A, Marenholz 
I, et al. High-density genotyping study identifies four new susceptibility loci for atopic 
dermatitis. Nat Genet. 2013;45(7):808-12. 
9. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-
ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new 
risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449-56. 
10. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and 
allergic diseases. N Engl J Med. 2011;365(14):1315-27. 
11. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Kakinuma T, et al. Interleukin-
13 gene polymorphism G4257A is associated with atopic dermatitis in Japanese patients. J 
Dermatol Sci. 2002;30(2):100-7. 
12. Esparza-Gordillo J, Schaarschmidt H, Liang L, Cookson W, Bauerfeind A, Lee-Kirsch 
MA, et al. A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic 
dermatitis. J Allergy Clin Immunol. 2013;132(2):371-7. 
13. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, 
Sawcer S, Lander ES, Daly MJ, et al. Low-Frequency and Rare-Coding Variation Contributes 
to Multiple Sclerosis Risk. Cell. 2018;175(6):1679-87 e7. 
14. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis 
of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285-91. 
15. Nothlings U, Krawczak M. [PopGen. A population-based biobank with prospective 
follow-up of a control group]. Bundesgesundheitsblatt Gesundheitsforschung 
Gesundheitsschutz. 2012;55(6-7):831-5. 
16. Wichmann HE, Gieger C, Illig T, Group MKS. KORA-gen--resource for population 
genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen. 2005;67 
Suppl 1:S26-30. 
17. Schmermund A, Mohlenkamp S, Stang A, Gronemeyer D, Seibel R, Hirche H, et al. 
Assessment of clinically silent atherosclerotic disease and established and novel risk factors 
for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: 
rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of 
Coronary Calcium and Lifestyle. Am Heart J. 2002;144(2):212-8. 
 
26 
18. Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, et al. Cohort 
profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. 
19. Bisgaard H. The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): 
design, rationale, and baseline data from a longitudinal birth cohort study. Ann Allergy 
Asthma Immunol. 2004;93(4):381-9. 
20. Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, et al. Shared 
genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat Genet. 
2017;49(12):1752-7. 
21. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. 
Systematic identification of trans eQTLs as putative drivers of known disease associations. 
Nat Genet. 2013;45(10):1238-43. 
22. Fehrmann RS, Jansen RC, Veldink JH, Westra HJ, Arends D, Bonder MJ, et al. Trans-
eQTLs reveal that independent genetic variants associated with a complex phenotype 
converge on intermediate genes, with a major role for the HLA. PLoS Genet. 
2011;7(8):e1002197. 
23. Mashima R, Hishida Y, Tezuka T, Yamanashi Y. The roles of Dok family adapters in 
immunoreceptor signaling. Immunol Rev. 2009;232(1):273-85. 
24. Mihrshahi R, Barclay AN, Brown MH. Essential roles for Dok2 and RasGAP in 
CD200 receptor-mediated regulation of human myeloid cells. J Immunol. 2009;183(8):4879-
86. 
25. Holmannova D, Kolackova M, Kondelkova K, Kunes P, Krejsek J, Andrys C. 
CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory 
responses; Part I: CD200/CD200R structure, activation, and function. Acta Medica (Hradec 
Kralove). 2012;55(1):12-7. 
26. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 
inhibition of mast cell activation. J Immunol. 2004;173(11):6786-93. 
27. Boulay I, Nemorin JG, Duplay P. Phosphotyrosine binding-mediated oligomerization 
of downstream of tyrosine kinase (Dok)-1 and Dok-2 is involved in CD2-induced Dok 
phosphorylation. J Immunol. 2005;175(7):4483-9. 
28. Mihrshahi R, Brown MH. Downstream of tyrosine kinase 1 and 2 play opposing roles 
in CD200 receptor signaling. J Immunol. 2010;185(12):7216-22. 
29. Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S. In vivo expression 
pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS One. 
2007;2(6):e518. 
30. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set 
analysis of GWAS data. PLoS Comput Biol. 2015;11(4):e1004219. 
31. Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic 
dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to 
psoriasis. J Invest Dermatol. 2019. 
32. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat 
Rev Dis Primers. 2018;4(1):1. 
33. Abramson J, Rozenblum G, Pecht I. Dok protein family members are involved in 
signaling mediated by the type 1 Fcepsilon receptor. Eur J Immunol. 2003;33(1):85-91. 
34. Gerard A, Favre C, Garcon F, Nemorin JG, Duplay P, Pastor S, et al. Functional 
interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine 
kinase. Oncogene. 2004;23(8):1594-8. 
35. Yasuda T, Bundo K, Hino A, Honda K, Inoue A, Shirakata M, et al. Dok-1 and Dok-2 
are negative regulators of T cell receptor signaling. Int Immunol. 2007;19(4):487-95. 
36. Di Cristofano A, Carpino N, Dunant N, Friedland G, Kobayashi R, Strife A, et al. 
Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding 
proteins. J Biol Chem. 1998;273(9):4827-30. 
 
27 
37. Gugasyan R, Quilici C, I ST, Grail D, Verhagen AM, Roberts A, et al. Dok-related 
protein negatively regulates T cell development via its RasGTPase-activating protein and Nck 
docking sites. J Cell Biol. 2002;158(1):115-25. 
38. Shinohara H, Inoue A, Toyama-Sorimachi N, Nagai Y, Yasuda T, Suzuki H, et al. 
Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling. J Exp 
Med. 2005;201(3):333-9. 
39. Mashima R, Arimura S, Kajikawa S, Oda H, Nakae S, Yamanashi Y. Dok adaptors 
play anti-inflammatory roles in pulmonary homeostasis. Genes Cells. 2013;18(1):56-65. 
40. Celis-Gutierrez J, Boyron M, Walzer T, Pandolfi PP, Jonjic S, Olive D, et al. Dok1 
and Dok2 proteins regulate natural killer cell development and function. EMBO J. 
2014;33(17):1928-40. 
41. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner 
A, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol. 
2010;28(10):1045-8. 
42. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and 




Table 1 – Exome chip discovery and replication genotyping as well as UK Biobank replication (self-reported AD) single-marker association 
analysis revealed DOK2 and CD200R1 as genome-wide significant AD susceptibility genes. Since exome chip discovery and replication 
genotyping studies comprised only AD patients ascertained by a dermatologist in comparison to the UK Biobank replication study with only self-
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UK Biobank summary statistics for 
AD, allergic rhinitis and/or hayfever (self-
reported) 
UK Biobank summary statistics for  




















8:21767240 DOK2 missense A/G 0.027 0.029 83,407/277,120 3.35×10-6 0.025 0.029 9,312/351,820 2.50×10-3 
rs9865242 
E312Q 
3:112642568 CD200R1 missense C/G 0.474 0.467 83,407/277,120 1.35×10-8 0.487 0.468 9,312/351,820 8.33×10-8 
 
AA, amino acid; chr, chromosome of the marker; bp, genomic position from NCBI dbSNP build v150 (genome build hg19); Gene, candidate gene; 
A1, minor allele; A2, major allele; AF, allele frequency of A1; OR, estimated odds ratio; P-values and ORs were calculated with respect to the minor 
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allele; genome-wide significant p-values (p < 5×10-8) are indicated in bold. All AD cases from discovery and replication panels had been diagnosed 
with AD (eczema) by a dermatologist. rs34215892 and rs9865242 were genotyped (non-imputed) in discovery and replication panels (except for the 
EAGLE GWAS replication data). Association results of UK Biobank (self-reported phenotypes; see Supplementary Table E1 in Online Repository) 
are listed separately. 
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Table 2 – Meta-analysis of gene-based aggregation tests for DOK2 increased the genome-wide significant association signal by more than two 
orders of magnitude in comparison to single-marker analysis (Table 1), indicating that multiple rare variants (with 10 out of 12 variants 
predicted to be pathogenic; Figure 1) contribute to the association signal. 
Gene dbSNP ID 
Position 
(chr:bp) 
























rs145725971* 8:21767033 0.00065 H343R Tolerated, possibly damaging 
rs145405180# 8:21767148 0.00139 A305T Tolerated, benign 
rs34215892# 8:21767240 0.03708 P274L 
Damaging, probably 
damaging 
rs74909419* 8:21767265 0.00019 R266W 
Damaging, probably 
damaging 
rs141482665* 8:21767322 0.00012 N247D Tolerated, probably damaging 
rs200168233* 8:21767414 0.00015 R216H 
Damaging, probably 
damaging 
rs200503110# 8:21767417 0.00019 R215H 
Damaging, probably 
damaging 
rs149080191* 8:21768370 0.00009 E.S.S. 
 
 
rs56094005# 8:21769432 0.04026 L138S 
Damaging, probably 
damaging 
rs201025320# 8:21770011 0.00003 R25H 
Damaging, probably 
damaging 






AA, amino acid substitution; E.S.S., essential splice site; Gene, candidate gene; Chr, chromosome of the marker; Bp, genomic position from NCBI 
dbSNP build v150 (genome build hg19); AFmean, mean allele frequency of minor allele from discovery panels (see Supplementary Table E5 in Online 
Repository); Prediction, SIFT prediction, PolyPhen-2 prediction; pSKAT, p of Sequence Kernel Association Test; Bonferroni-corrected exome chip 
significant gene-based p-values (pgene < 0.05/15,998=3×10
-6; 15,998 genes) are indicated in bold. Cohort specific association details are given in 
Supplementary Table E6 in Online Repository. *, risk variant (in context of the odds ratio); #, protective variant. All 12 variants were genotyped 
(non-imputed) in the discovery and replication panels (except for the EAGLE GWAS replication data).
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Figure 1 – Exome chip association analysis identified two low-frequency (rs34215892 and 
rs56094005; 1 % ≤ MAF < 5 %) and ten rare (MAF < 1 %) coding variants contributing 
to the genome-wide significant association signal at DOK2 (pDOK2 = 4.23×10-13; Table 2). 
Minor allele frequency in AD cases (dark blue) and controls (light blue) are shown from 
discovery exome chip meta-analysis (see Supplementary Table E1 in Online Repository). 10 
out of 12 variants were predicted to be pathogenic (see Methods in Online Repository), 
suggesting that multiple missense variants contribute to the gene-based association signal. Both 
low-frequency lead variants are LD-independent (r2rs56094005-rs34215892 = 0.0015). Variant effect 
predictions (by SIFT and PolyPhen-2) depicted in red (white or grey) represent amino acid 
substitutions predicted to be potentially damaging (probably not damaging or prediction not 
possible). SNV – single nucleotide variant; ESS – essential splice site; pos – amino acid 
position; PP – PolyPhen-2. PH – Pleckstrin-homology domain; PTB – Phosphotyrosine-binding 
domain; PRR1 – Prolin-rich region 1; PRR2 – Prolin-rich region 2. A – Alanine; D – Aspatic 
acid; F – Phenylalanine; H – Histidine; L – Leucin; N – Asparagine; P – Proline; R – Arginine; 




Figure 2 – Hypothetical model constructed from protein sequence and structural domain 
analysis suggesting that missense lead variants rs56094005, rs34215892 (p.L138S and 
p.P274L; DOK2) and rs9865242 (p.E312Q; CD200R1) are located near functionally 
important tyrosine phosphorylation sites and may interfere with CD200/CD200R1 
receptor complex and DOK2 function.  
We assume a simplified illustration of DOK2 function in response to CD200R1 in human 
myeloid cells(41) in which CD200/CD200R1 binding leads to tyrosine phosphorylation of the 
NPLY motif in the cytoplasmic tail of CD200R1 and the recruitment of the DOK2 adapter 
protein(24). DOK2 interaction with CD200R1 leads to DOK2 tyrosine phosphorylation at 
positions Y271/Y299 (activating RasGAP) and Y139 (activating DOK1), which leads to the 
recruitment of RasGAP and its subsequent activation(28). 
Interacting CD200 and CD200R1 extracellular domains are visualized as structural models 
received from the Protein Databank (PDB ID 4bfi), while CD200R1 transmembrane and 
cytoplasmic tail is shown as blue lines. Variants are highlighted in red to indicate their relative 
positions within protein domains. The structural effect of protein variants cannot be modelled 
in 3D due to the lack of structural templates in the PDB for the concerned regions. Interactions 
between proteins are visualized as solid lines, following events as dashed lines. Cell membranes 
anchoring the receptors are illustrated in orange-grey. DOK2 domains were abbreviated as PH: 







Figure 3 – Multiomics-based network interaction analysis unveiled topologically and functionally important AD susceptibility genes and 
determined DOK2 as a central hub node interacting with CD200R1 and candidate susceptibility genes (marked with white asterisk) identified 
by previous large AD consortium GWAS. (A) The majority of core genes (n = 22 out of 30; including DOK2) shows significantly upregulated and 
downregulated gene expression levels (depicted by black upwards and downwards arrows) in whole transcriptome mRNA-seq data (“AD-L”; “AD-
NL” and “healthy”; see also Supplementary Table E9 in Online Repository). Grey-striped nodes (n = 10, including DOK2) represent the most relevant 
genes from topological network analysis, with two light grey-striped nodes representing genes not interacting with DOK2 and seven dark grey-striped 
nodes representing genes directly interacting with DOK2. Non-striped nodes (n = 20) represent genes additionally added by a functional similarity 
search, with six light grey non-striped nodes not directly interacting with DOK2 and 14 dark grey non-striped nodes directly interacting with DOK2. 







Figure 4 – Tissue specificity analysis using 53 tissue types from GTEx identifies a 
significant positive relationship between skin tissue gene expression profiles and exome 
chip association statistics. Exome chip single variant association score statistics (exome chip 
data set) and GWAS SNP association summary statistics from the EAGLE Eczema Consortium 
(GWAS data set), respectively, were converted to AD-gene association Z scores using a 
multiple linear principal components regression model as implemented in MAGMA(30) 
thereby ensuring that LD between SNPs is accounted for (see in Online Repository Methods). 
We conducted tissue specificity analysis with FUMA(42) to test for a positive relationship 
between tissue-specific gene expression profiles constructed from 53 tissue types and 11,688 
samples from GTEx v7 and AD-gene associations (either from exome chip or GWAS data set) 
represented by gene-based Z scores (see in Online Repository Methods). We used Bonferroni 
correction p < 0.05/53 = 9.43×10-4 as significance cut-off. (a) The exome chip data set revealed 
a positive relationship between gene expression profiles from skin tissues "sun exposed” and 
“non-sun exposed” and AD-gene associations. (b) In comparison, the GWAS data set showed 
an association with tissues “whole blood” and “spleen”.  
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